ERBB2 and breast carcinoma: Nowadays, integrated models are used to make treatment decisions about escalation or de-escalation of either endocrine therapy or chemotherapy for early-stage, hormonal receptor (HR)-positive, HER2/neu-negative breast cancer, with the consideration of both anatomical and biologic risk [1].